GlobeNewswire PharmaOriginal article
Tasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155)
Patent ExpiryTSRF-786CPositive
AI Analysis
Summary
Tasrif Pharmaceutical announced the grant of a second U.S. patent for humanized monoclonal antibodies targeting poliovirus receptor (CD155), with the lead candidate TSRF-786C demonstrating sub-nanomolar affinity and potential applications in antibody-drug conjugates and bispecific therapeutics.
Outcome Details
Grant of second U.S. patent for humanized monoclonal antibodies against poliovirus receptor (CD155)
Importance:4/10
Sentiment:
0.60
PatentMonoclonal AntibodyCD155ADCBispecific
Read the original article
Published by GlobeNewswire Pharma on July 29, 2026 9:30 AM